Subcellular localization of p27 and prostate cancer recurrence: Automated digital microscopy analysis of tissue microarrays

Human Pathology

Volumn 42, Issue 6, 2011, Pages 873-881

  Ananthanarayanan, Viju ^a   Deaton, Ryan J ^a   Amatya, Anup ^a   MacIas, Virgilia ^a   Luther, Ed ^b   Kajdacsy Balla, Andre ^a   Gann, Peter H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b CompuCyte Corporation ^*  (United States)

Author keywords

Automated image analysis; p27Kip1; Prognosis; Prostate cancer; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27;

ANTIBODY LABELING; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CYTOPLASM; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER SCANNING CYTOMETRY; NUCLEAR LOCALIZATION SIGNAL; PROGNOSIS; PROSTATE CANCER; RECURRENCE RISK; RISK ASSESSMENT; TISSUE MICROARRAY; TISSUE SECTION; TUMOR VOLUME;

ADENOCARCINOMA; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956109461     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.10.006     Document Type: Article

References (29)

1. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8. (Pubitemid 28087420)
2. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5. (Pubitemid 28106561)
3. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000;164:2156-61.
4. Drobnjak M, Melamed J, Taneja S, et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 2003;9:2613-9. (Pubitemid 36842104)
5. Sgambato A, Ratto C, Faraglia B, et al. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27 (Kip1) in human colon cancer. Mol Carcinog 1999;26:172-9. (Pubitemid 29529568)
6. Li R, Wheeler TM, Dai H, et al. Biological correlates of p27 compartmental expression in prostate cancer. J Urol 2006;175:528-32. (Pubitemid 43067345)
7. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006;130:1026-30. (Pubitemid 44061434)
8. Kajdacsy-Balla A, Geynisman JM, Macias V, et al. Practical aspects of planning, building, and interpreting tissue microarrays: the cooperative prostate cancer tissue resource experience. J Mol Histol 2007;38:113-21. (Pubitemid 46659332)
9. Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20. (Pubitemid 28304160)
10. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5. (Pubitemid 27355479)
11. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4. (Pubitemid 27064711)
12. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5. (Pubitemid 27064709)
13. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997;3(Pt 1):2269-74. (Pubitemid 28133145)
14. Kuczyk M, Machtens S, Hradil K, et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 1999;81:1052-8. (Pubitemid 29516151)
15. Freedland SJ, de Gregorio F, Sacoolidge JC, et al. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology 2003;61:1187-92. (Pubitemid 36694000)
16. Erdamar S, Yang G, Harper JW, et al. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 1999;12:751-5. (Pubitemid 29383876)
17. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-9. (Pubitemid 36418404)
18. Nguyen PL, Lin DI, Lei J, et al. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol 2009.
19. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
20. Myers RB, Oelschlager DK, Coan PN, et al. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma. J Urol 1999;161:945-9. (Pubitemid 29422413)
21. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8:3419-26. (Pubitemid 35340716)
22. Orend G, Hunter T, Ruoslahti E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 1998;16:2575-83. (Pubitemid 28264035)
23. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5. (Pubitemid 28215101)
24. Psyrri A, Bamias A, Yu Z, et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 2005;11:8384-90. (Pubitemid 41746951)
25. Watanabe J, Sato H, Kanai T, et al. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Br J Cancer 2002;87:81-5.
26. Cheng JD, Werness BA, Babb JS, Meropol NJ. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999;5:1057-62. (Pubitemid 29233219)
27. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL, Hansel DE. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am J Clin Pathol 2003;120:685-90. (Pubitemid 37339674)
28. Moeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol 2009;520:163-75.
29. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008;26:5630-7.